

ATTACHMENT B

Marked Up Replacement Claims

Following herewith is a marked up copy of each rewritten claim.

7. (Amended) Expression vector comprising an expression cassette in which a nucleotide sequence as defined in ~~one of Claims 1 to 4~~ Claim 1 is placed under conditions allowing its expression in a host cell.
9. Canceled.
10. (Amended) Monospecific antibody directed against a polypeptide according to ~~either of Claims 5 and 6~~ Claim 5.
11. (Amended) Use of a nucleic acid according to ~~one of Claims 1 to 4~~ Claim 1, or of a polypeptide specific for pathogenic *Neisseria* strains or of antigenic fragments thereof, according to ~~either of Claims 5 and 6~~ for manufacturing a pharmaceutical composition intended for vaccination against *Neisseria*.
12. (New) A pharmaceutical composition comprising a nucleic acid according to Claim 1, in naked form or in combination with at least one agent facilitating transfection, and optionally in combination with a pharmaceutically acceptable vehicle.

13. (New) A pharmaceutical composition comprising a vaccination vector comprising a nucleotide sequence according to Claim 1, such as in particular a virus or a bacterium, and optionally in combination with a pharmaceutically acceptable vehicle.

14. (New) A pharmaceutical composition comprising a polypeptide according to Claim 5, optionally in combination with a pharmaceutically acceptable vehicle.